Inhibiting surface enhanced crystallization of amorphous pharmaceuticals with ultrathin coatings
US9254266B2 · kind B2 · utility
0Cited by
3References
32Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 21, 2008 |
| Grant date | Feb 9, 2016 |
| Priority date | — |
| Expiry date | Jun 7, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/4422
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides surface-stabilized amorphous pharmaceuticals comprising an amorphous pharmaceutical substrate coated with a biocompatible immobilizing material. Amorphous pharmaceutical substrates that are prone to surface enhanced crystallization benefit from the present coatings. The coated amorphous pharmaceuticals of the present invention maintain their amorphous state and, therefore, their solubility over extended periods of time, relative to uncoated pharmaceuticals.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.